Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0205 | 0.3631 | 1 |
Brugia malayi | Dihydrofolate reductase | 0.0537 | 1 | 1 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0537 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0029 | 0.0237 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0205 | 0.3631 | 0.5 |
Schistosoma mansoni | dihydrofolate reductase | 0.0537 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0032 | 0.0308 | 0.0239 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0032 | 0.0308 | 0.0208 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0537 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0032 | 0.0308 | 0.0239 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0032 | 0.0308 | 0.0239 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0032 | 0.0308 | 0.0308 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0032 | 0.0308 | 0.0239 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0205 | 0.3631 | 1 |
Leishmania major | p450 reductase, putative | 0.0032 | 0.0308 | 0.0208 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0537 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0032 | 0.0308 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0205 | 0.3631 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0032 | 0.0308 | 0.0239 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.002 | 0.0071 | 0.0071 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0032 | 0.0308 | 0.0239 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0537 | 1 | 1 |
Echinococcus multilocularis | dihydrofolate reductase | 0.0537 | 1 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.0537 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0308 | 0.0239 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0205 | 0.3631 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0205 | 0.3631 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0032 | 0.0308 | 0.0239 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0032 | 0.0308 | 0.0208 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0537 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0029 | 0.0237 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Activity against rat cerebellum iNOS upto 1 uM | ChEMBL. | 17315988 | |
Activity (binding) | 0 | Activity against rat cerebellum iNOS upto 1 uM | ChEMBL. | 17315988 |
IC50 (binding) | = 150 nM | Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation | ChEMBL. | 17315988 |
IC50 (binding) | = 150 nM | Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation | ChEMBL. | 17315988 |
IC50 (binding) | = 260 nM | Inhibition of vaccinia virus system-induced human NOS expressed in BSC1 cells | ChEMBL. | 17315988 |
Ratio IC50 (binding) | = 3 | Selectivity ratio, IC50 for bcNOS/IC50 for iNOS using vaccinia virus-induced system in BSC1 cells | ChEMBL. | 17315988 |
Ratio IC50 (binding) | = 70 | Selectivity ratio, IC50 for ecNOS/IC50 for iNOS using vaccinia virus-induced system in BSC1 cells | ChEMBL. | 17315988 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.